Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jul;8(4):347-56.
doi: 10.1161/CIRCOUTCOMES.114.001223. Epub 2015 Jun 2.

Early Medication Nonadherence After Acute Myocardial Infarction: Insights into Actionable Opportunities From the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study

Robin Mathews  1 , Eric D Peterson  2 , Emily Honeycutt  2 , Chee Tang Chin  2 , Mark B Effron  2 , Marjorie Zettler  2 , Gregg C Fonarow  2 , Timothy D Henry  2 , Tracy Y Wang  2
Affiliations
Randomized Controlled Trial

Early Medication Nonadherence After Acute Myocardial Infarction: Insights into Actionable Opportunities From the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study

Robin Mathews et al. Circ Cardiovasc Qual Outcomes. 2015 Jul.

Abstract

Background: Nonadherence to prescribed evidence-based medications after acute myocardial infarction (MI) can contribute to worse outcomes and higher costs. We sought to better understand the modifiable factors contributing to early nonadherence of evidence-based medications after acute MI.

Methods and results: We assessed 7425 acute MI patients treated with percutaneous coronary intervention at 216 US hospitals participating in TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) between April 2010 and May 2012. Using the validated Morisky instrument to assess cardiovascular medication adherence at 6 weeks post MI, we stratified patients into self-reported high (score, 8), moderate (score, 6-7), and low (score, <6) adherence groups. Moderate and low adherence was reported in 25% and 4% of patients, respectively. One third of low adherence patients described missing doses of antiplatelet therapy at least twice a week after percutaneous coronary intervention. Signs of depression and patient-reported financial hardship because of medication expenses were independently associated with a higher likelihood of medication nonadherence. Patients were more likely to be adherent at 6 weeks if they had follow-up appointments made before discharge and had a provider explain potential side effects of their medications. Lower medication adherence may be associated with a higher risk of 3-month death/readmission (adjusted hazard ratio, 1.35; 95% confidence interval, 0.98-1.87) although this did not reach statistical significance.

Conclusions: Even early after MI, a substantial proportion of patients report suboptimal adherence to prescribed medications. Tailored patient education and pre discharge planning may represent actionable opportunities to optimize patient adherence and clinical outcomes.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01088503.

Keywords: acute myocardial infarction; medication nonadherence; percutaneous coronary intervention.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures

R Mathews: Dr. Mathews has no relevant disclosures to report.

ED Peterson: Dr. Peterson reports research funding for the American College of Cardiology, American Heart Association, Eli Lilly & Company, Janssen Pharmaceuticals, and Society of Thoracic Surgeons (all significant); consulting (including CME) for Merck & Co. (modest), Boehringer Ingelheim, Genentech, Janssen Pharmaceuticals, and Sanofi-Aventis (all significant).

E Honeycutt: Ms. Honeycutt has no relevant disclosures to report.

CT Chin: Dr. Chin has no relevant disclosures to report.

MB Effron: Dr. Effron reports being an employee of Eli Lilly & Company; shareholder of Lilly, USA.

M Zettler: Dr. Zettler reports being an employee of Eli Lilly & Company.

GC Fonarow: Dr. Fonarow reports being a consultant to Novartis (significant) and Janssen (modest).

TD Henry: Dr. Henry has no relevant disclosures to report.

TY Wang: Dr. Wang reports research funding from AstraZeneca, Gilead, Lilly, The Medicines Company, and Canyon Pharmaceuticals (all significant); educational activities or lectures (generates money for Duke) for AstraZeneca (modest); consulting (including CME) for Medco (modest) and American College of Cardiology (significant).

Figures

Figure 1
Figure 1. Forest Plot
This figure displays significant factors associated with medication nonadherence. Other variables included in the model: gender, non-Hispanic, black race, smoker, cardiac rehab referral, EuroQol-5 Dimensions score, married, ≥high school graduation, employed, written discharge medication list/instructions, insurance coverage, assistance program to pay for medications, cardiac rehab participation. Moderate exercise= at least 1 day a week of ≥20 minutes of exercise. OR listed with 95% confidence intervals. OR, odds ratio
Figure 2
Figure 2. Rates of Death/Readmission
Kaplan Meier curves for rates of death/readmission within 120 days according to Morisky score. Variables included in the model: age, gender, race, ethnicity, insurance status, marital status, educational level, prior MI, prior PCI, prior CABG surgery, prior stroke or transient ischemic attack, peripheral arterial disease, prior heart failure, prior atrial fibrillation or flutter, diabetes, hypertension, dyslipidemia, dialysis, smoking status, chronic lung disease, recent gastrointestinal or genitourinary bleeding in the 6 months prior to index MI admission, STEMI presentation, cardiac arrest within 24 hours of admission, cardiogenic shock within 24 hours of admission, heart failure signs or symptoms within two weeks before admission, body mass index, admission heart rate, admission systolic blood pressure, pre-procedure hemoglobin, pre-procedure creatinine clearance, multivessel disease on angiography, multivessel PCI, bifurcating culprit lesion, culprit lesion involving a CABG graft, drug-eluting stent implantation, culprit lesion successfully dilated, left ventricular ejection fraction, transfer-in status, number of hospitalizations between index hospital discharge and the 6-week interview, and hospital referral region. CABG, coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction
See this image and copyright information in PMC

References

    1. Kochanek KD, Xu J, Murphy SL, Miniño AM, Kung HC. Division of Vital Statistics. Deaths: Final Data for 2009. [Updated December 29, 2011. Accessed October 3, 2013];National Vital Statistics Reports, Volume 60, Number 3. Centers for Disease Control and Prevention web site. http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_03.pdf. - PubMed
    1. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE, Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr, Chavey WE, 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Zidar JP. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;57:e215–e367. - PubMed
    1. Kushner FG, Hand M, Smith SC, Jr, King SB, 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE, Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271–2306. - PubMed
    1. Somma KA, Bhatt DL, Fonarow GC, Cannon CP, Cox M, Laskey W, Peacock WF, Hernandez AF, Peterson ED, Schwamm L, Saxon LA. Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012;5:654–661. - PubMed
    1. Hospital Compare. [Accessed June 3, 2013];Medicare.gov: The Official U.S. Government Site for Medicare web site. http://www.medicare.gov/hospitalcompare/?AspxAutoDetectCookieSupport=1.

Publication types

Substances

Associated data

LinkOut - more resources